Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 20;13:836635. doi: 10.3389/fphar.2022.836635

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Hoshino, Soma, Uchida, Shiko, Nakagome and Nagata.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Comparison of the future risk of asthma exacerbations after the entry between the type 2 biomarker-classified subgroups. (A) Differences in the number of annual subsequent asthma exacerbation after the entry among the subgroups classified by FeNO and B-EOS cutoff values for detection of sputum eosinophilia. Horizontal bars represent median. *vs. Low FeNO, High-b-EOS, p = 0.006; **vs. Low FeNO, Low-b-EOS, p = 0.01; ***vs. High FeNO, High-b-EOS, p = 0.04. (B) Kaplan–Meier analysis for asthma exacerbation-free time after the entry among the predominant type 2 inflammation subgroups. Generalized Wilcoxon, p = 0.048, Log Rank, p = 0.07. B-EOS, blood eosinophils; AE, asthma exacerbation.